Terns Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Terns Pharmaceuticals's earnings have been declining at an average annual rate of -13.8%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 123.1% per year.
Key information
-13.8%
Earnings growth rate
115.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 123.1% |
| Return on equity | -32.0% |
| Net Margin | -5,877.1% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Terns Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 1 | -59 | 22 | 38 |
| 30 Jun 22 | 1 | -54 | 21 | 33 |
| 31 Mar 22 | 1 | -51 | 21 | 31 |
| 31 Dec 21 | 1 | -50 | 20 | 31 |
| 30 Sep 21 | 0 | -35 | 15 | 30 |
| 30 Jun 21 | 0 | -35 | 14 | 28 |
| 31 Mar 21 | 0 | -34 | 11 | 30 |
| 31 Dec 20 | 0 | -29 | 9 | 28 |
| 30 Sep 20 | 0 | -40 | 10 | -7 |
| 31 Dec 19 | 0 | -69 | 9 | 27 |
Quality Earnings: 430 is currently unprofitable.
Growing Profit Margin: 430 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 430 is unprofitable, and losses have increased over the past 5 years at a rate of 13.8% per year.
Accelerating Growth: Unable to compare 430's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 430 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 430 has a negative Return on Equity (-31.99%), as it is currently unprofitable.